Surgical biopsy rather than needle biopsy is performed more often than it should be. About this I have no doubt. Anecdotal evidence of professional and financial bias in favor of surgery has been supported by surveys demonstrating that up to 80% of women
Surgical biopsy rather than needle biopsy is performed more often than it should be. About this I have no doubt. Anecdotal evidence of professional and financial bias in favor of surgery has been supported by surveys demonstrating that up to 80% of women undergoing biopsy see the edge of a scalpel rather than the tip of a needle. It is hard to believe that nearly a decade has passed since the first digital spot system for breast biopsy was commercialized.
It is easy to lament the low payment afforded minimally invasive biopsy compared with surgery. Medicare pays around $400 for surgical biopsy but only $128 if the job is done with a needle. Professional fees paid by private insurers are similarly unbalanced, but these do not begin to reflect the true costs. The additional requirements of surgery-general anesthesia, an OR, support staff, a recovery room-bump the total cost of surgery to $3000 or more. Then there are the personal costs to the patient: unnecessary discomfort and possible disfigurement.
Why is this happening? The fault, to paraphrase shamelessly, lies not in the stars but in ourselves. It is human nature to recommend what we know. Most ob/gyns have traditionally recommended patients to surgeons for biopsy. Surgeons do surgery.
If surgeons were given both the equipment and the financial incentive to use needle biopsy, the practice of medicine would almost certainly change. But that is a tall order. Surgeons must first want to buy the equipment, and insurers must want to change the reimbursement rate. The means to both ends might be found in a grassroots effort to educate patients about the advantages of needle biopsy.
Women’s health advocates are an influential segment of society. Some vendors have already sought the help of these groups to win support for full-field digital mammography. It makes at least as much sense to seek their help in educating women about the advantages of needle biopsy, while simultaneously pushing for changes in reimbursement rates that favor this procedure. Promoting this technology through a strategic effort coordinated by radiology vendors is not only the smart thing to do, it is the right thing to do.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Current Perspectives on Radiology Workforce Issues and Potential Solutions
March 14th 2024Emphasizing the gravity of the ongoing workforce shortage in radiology, these authors recommend a change agenda focusing on expanded numbers of residency positions, reassessment of educational pathways, maintaining a strong presence in hospital settings and practice level initiatives to reduce administrative burden and achieve appropriate reimbursement beyond RVU measurements.
Could Cloud-Based 'Progressive Loading' be a Boon for Radiology Workflows?
March 13th 2024The newly launched Progressive Loading feature, available through RamSoft’s OmegaAI software, reportedly offers radiologist rapid uploading of images that is faster than on-site networks and other cloud-based systems regardless of the network radiologists are using.